CytomX Therapeutics Inc

+0.21 (+5.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)272.22M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.57 Million
Adjusted EPS-$0.35
See more estimates
10-Day MA$4.03
50-Day MA$5.77
200-Day MA$6.20
See more pivots

CytomX Therapeutics Inc Stock, NASDAQ:CTMX

151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080-1913
United States of America
Phone: +1.605.515.3185
Number of Employees: 146


CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.